The role of local therapy in the management of lung and liver oligometastases

Nature Reviews Clinical Oncology

Volumn 8, Issue 7, 2011, Pages 405-416

  Lo, Simon S ^a   Moffatt Bruce, Susan D ^b   Dawson, Laura A ^c   Schwarz, Roderich E ^d   Teh, Bin S ^e   Mayr, Nina A ^f   Lu, Jiade J ^g   Grecula, John C ^f   Olencki, Thomas E ^f   Timmerman, Robert D ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LIVER RESECTION; LOCAL THERAPY; LUNG COMPLICATION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SURGERY; METASTASIS; OLIGOMETASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PORTAL VEIN; PORTAL VEIN EMBOLIZATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PULMONARY METASTASECTOMY; RADIATION DOSE FRACTIONATION; RADIOFREQUENCY ABLATION; REVIEW; SARCOMA; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING;

HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS;

EID: 79959961573     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.75     Document Type: Review

References (140)

1. Hellman, S. & Weichselbaum, R. R. Oligometastases revisited. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2011.44.
2. Lo, S. S. et al. Stereotactic body radiation therapy for oligometastases. Expert Rev. Anticancer Ther. 9, 621-635 (2009).
3. [No authors listed] Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J. Thorac. Cardiovasc. Surg. 113, 37-49 (1997).
4. Onaitis, M. W. et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann. Thorac. Surg. 87, 1684-1688 (2009).
5. Petersen, R. P. et al. Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma. J. Thorac. Cardiovasc. Surg. 133, 104-110 (2007).
6. Fong, Y. et al. Liver resection for colorectal metastases. J. Clin. Oncol. 15, 938-946 (1997). (Pubitemid 27106275)
7. Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F. & Blumgart, L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann. Surg. 230, 309-318 (1999).
8. Choti, M. A. et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 235, 759-766 (2002). (Pubitemid 34547293)
9. Kopetz, S. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27, 3677-3683 (2009).
10. Pawlik, T. M. et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241, 715-722 (2005).
11. Fernandez, F. G. et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann. Surg. 240, 438-447 (2004).
12. Timmerman, R. D. et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J. Clin. 59, 145-170 (2009).
13. Lo, S. S. et al. Stereotactic body radiation therapy: A novel treatment modality. Nat. Rev. Clin. Oncol. 7, 44-54 (2010).
14. Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27, 1579-1584 (2009).
15. Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572-1578 (2009).
16. Lee, M. T. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27, 1585-1591 (2009).
17. Rule, W. et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann. Surg. Oncol. 18, 1081-1087 (2011).
18. Le, Q. T. et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J. Thorac. Oncol. 1, 802-809 (2006).
19. Okunieff, P. et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 45, 808-817 (2006). (Pubitemid 44423126)
20. Katz, A. W. et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int. J. Radiat. Oncol. Biol. Phys. 67, 793-798 (2007). (Pubitemid 46215888)
21. Herfarth, K. K. et al. Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J. Clin. Oncol. 19, 164-170 (2001). (Pubitemid 32063493)
22. Hof, H., Hoess, A., Oetzel, D., Debus, J. & Herfarth, K. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther. Onkol. 183, 673-678 (2007). (Pubitemid 350175409)
23. Zhu, J. C., Yan, T. D. & Morris, D. L. A systematic review of radiofrequency ablation for lung tumors. Ann. Surg. Oncol. 15, 1765-1774 (2008).
24. Norton, L. & Simon, R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70, 163-169 (1986). (Pubitemid 16140378)
25. Mehta, N. et al. Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment. Int. J. Oncol. 25, 1677-1683 (2004).
26. Rusthoven, K. E. et al. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 48, 578-583 (2009).
27. Kavanagh, B. D., McGarry, R. C. & Timmerman, R. D. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin. Radiat. Oncol. 16, 77-84 (2006).
28. Ollila, D. W. & Caudle, A. S. Surgical management of distant metastases. Surg. Oncol. Clin. N. Am. 15, 385-398 (2006).
29. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Colon Cancer [online], http://www.nccn.org/professionals/physician- gls/pdf/colon.pdf (2011).
30. Welter, S., Jacobs, J., Krbek, T., Krebs, B. & Stamatis, G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann. Thorac. Surg. 84, 203-210 (2007). (Pubitemid 46921140)
31. Pfannschmidt, J., Dienemann, H. & Hoffmann, H. Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series. Ann. Thorac. Surg. 84, 324-338 (2007). (Pubitemid 46921128)
32. Riquet, M. et al. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann. Thorac. Surg. 89, 375-380 (2010).
33. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma [online], http://www.nccn.org/professionals/ physician-gls/pdf/sarcoma.pdf (2011).
34. Suri, R. M. et al. Pulmonary resection for metastatic malignant fibrous histiocytoma: An analysis of prognostic factors. Ann. Thorac. Surg. 80, 1847-1852 (2005). (Pubitemid 41464312)
35. Blackmon, S. H. et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann. Thorac. Surg. 88, 877-884 (2009).
36. Assouad, J. et al. Renal cell carcinoma lung metastases surgery: Pathologic findings and prognostic factors. Ann. Thorac. Surg. 84, 1114-1120 (2007). (Pubitemid 47417869)
37. Murthy, S. C. et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann. Thorac. Surg. 79, 996-1003 (2005). (Pubitemid 40288764)
38. Balch, C. M. et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622-3634 (2001). (Pubitemid 32786275)
39. Clavero, J. M. et al. Gynecologic cancers: Factors affecting survival after pulmonary metastasectomy. Ann. Thorac. Surg. 81, 2004-2007 (2006). (Pubitemid 43775527)
40. Shiono, S. et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann. Thorac. Surg. 88, 856-860 (2009).
41. Winter, H. et al. Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann. Surg. Oncol. 15, 2915-2926 (2008).
42. Virgo, K. S., Naunheim, K. S. & Johnson, F. E. Preoperative workup and postoperative surveillance for patients undergoing pulmonary metastasectomy. Thorac. Surg. Clin. 16, 125-131 (2006). (Pubitemid 43728428)
43. Mineo, T. C., Ambrogi, V., Mineo, D. & Pompeo, E. Transxiphoid hand-assisted videothoracoscopic surgery. Ann. Thorac. Surg. 83, 1978-1984 (2007). (Pubitemid 46782672)
44. Lo, S. S. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Rev. Anticancer Ther. 8, 87-98 (2008).
45. Fakiris, A. J. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study. Int. J. Radiat. Oncol. Biol. Phys. 75, 677-682 (2009).
46. Ernst-Stecken, A., Lambrecht, U., Mueller, R., Sauer, R. & Grabenbauer, G. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: First results of a phase I/II study. Strahlenther. Onkol. 182, 696-702 (2006). (Pubitemid 44887170)
47. Forquer, J. A. et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites. Radiother. Oncol. 93, 408-413 (2009).
48. Timmerman, R. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 24, 4833-4839 (2006). (Pubitemid 46630909)
49. Norihisa, Y. et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 72, 398-403 (2008).
50. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
51. Donadon, M., Ribero, D., Morris-Stiff, G., Abdalla,E. K. & Vauthey, J. N. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest. Cancer Res. 1, 20-27 (2007).
52. Abdalla, E. K. et al. Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann. Surg. Oncol. 13, 1271-1280 (2006). (Pubitemid 44435793)
53. Hughes, K. S. et al. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence. Surgery 100, 278-284 (1986). (Pubitemid 16070861)
54. Scheele, J., Stangl, R. & Altendorf-Hofmann, A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br. J. Surg. 77, 1241-1246 (1990).
55. Charnsangavej, C. et al. Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann. Surg. Oncol. 13, 1261-1268 (2006). (Pubitemid 44435791)
56. Fong, Y., Gonen, M., Rubin, D., Radzyner, M. & Brennan, M. F. Long-term survival is superior after resection for cancer in high-volume centers. Ann. Surg. 242, 540-544 (2005).
57. Mainenti, P. P. et al. Detection of colo-rectal liver metastases: Prospective comparison of contrast enhanced US, multidetector, CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom. Imaging 35, 511-521 (2010).
58. Rappeport, E. D. et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: A prospective study with intraoperative confirmation. Acta Radiol. 48, 369-378 (2007). (Pubitemid 46633866)
59. Carpizo, D. R. et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: Results in 127 patients treated at a single center. Ann. Surg. Oncol. 16, 2138-2146 (2009).
60. Pawlik, T. M. et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann. Surg. Oncol. 16, 371-378 (2009).
61. Parks, R. et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents. J. Am. Coll. Surg. 204, 753-761 (2007). (Pubitemid 46661187)
62. Nordlinger, B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371, 1007-1016 (2008). (Pubitemid 351392040)
63. Reddy, S. K. et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann. Surg. Oncol. 16, 1809-1819 (2009).
64. Adam, R. et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann. Surg. 240, 1052-1061 (2004).
65. Blazer, D. G. 3rd et al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J. Clin. Oncol. 26, 5344-5351 (2008).
66. Gallagher, D. J. et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann. Surg. Oncol. 16, 1844-1851 (2009).
67. Scoggins, C. R. et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann. Surg. Oncol. 16, 35-41 (2009).
68. Adam, R. et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J. Clin. Oncol. 27, 1829-1835 (2009).
69. Bismuth, H. et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224, 509-520 (1996).
70. Sarpel, U. et al. Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann. Surg. Oncol. 16, 379-384 (2009).
71. Reddy, S. K. et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: A multi-institutional analysis. Ann. Surg. Oncol. 14, 3481-3491 (2007). (Pubitemid 350160107)
72. Martin, R. et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J. Am. Coll. Surg. 197, 233-241 (2003).
73. Schwarz, R. E. Visceral organ resections combined with synchronous major hepatectomy: Examples of safety and feasibility. HPB 5, 27-32 (2003). (Pubitemid 36503164)
74. Wicherts, D. A. et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann. Surg. 248, 994-1005 (2008).
75. Chun, Y. S. et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: Perioperative safety and survival. J. Gastrointest. Surg. 11, 1498-1504 (2007).
76. Ribero, D. et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br. J. Surg. 94, 1386-1394 (2007). (Pubitemid 350144388)
77. Covey, A. M. et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann. Surg. 247, 451-455 (2008).
78. Poon, R. T. et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: Analysis of 1222 consecutive patients from a prospective database. Ann. Surg. 240, 698-708 (2004).
79. Gold, J. S. et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: Trends in treatment over time in 440 patients. Ann. Surg. 247, 109-117 (2008).
80. Jarnagin, W. R. et al. Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade. Ann. Surg. 236, 397-406 (2002).
81. Rees, M., Tekkis, P. P., Welsh, F. K., O'Rourke, T. & John, T. G. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann. Surg. 247, 125-135 (2008).
82. de Haas, R. J. et al. R1 resection by necessity for colorectal liver metastases: Is it still a contraindication to surgery? Ann. Surg. 248, 626-637 (2008).
83. de Jong, M. C. et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann. Surg. 250, 440-448 (2009).
84. Scheele, J., Stang, R., Altendorf-Hofmann, A. & Paul, M. Resection of colorectal liver metastases. World J. Surg. 19, 59-71 (1995).
85. Tomlinson, J. S. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol. 25, 4575-4580 (2007). (Pubitemid 350035315)
86. Brachet, D. et al. Prognostic factors of survival in repeat liver resection for recurrent colorectal metastases: Review of sixty-two cases treated at a single institution. Dis. Colon Rectum 52, 475-483 (2009).
87. Ishiguro, S. et al. Second hepatectomy for recurrent colorectal liver metastasis: Analysis of preoperative prognostic factors. Ann. Surg. Oncol. 13, 1579-1587 (2006). (Pubitemid 44951465)
88. Sa Cunha, A. et al. A second liver resection due to recurrent colorectal liver metastases. Arch. Surg. 142, 1144-1149 (2007). (Pubitemid 350301911)
89. Shaw, I. M., Rees, M., Welsh, F. K., Bygrave, S. & John, T. G. Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br. J. Surg. 93, 457-464 (2006).
90. Thelen, A. et al. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur. J. Surg. Oncol. 33, 324-328 (2007). (Pubitemid 46499229)
91. Kattan, M. W. et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann. Surg. 247, 282-287 (2008). (Pubitemid 351156771)
92. Adam, R. et al. Hepatic resection for noncolorectal nonendocrine liver metastases: Analysis of 1,452 patients and development of a prognostic model. Ann. Surg. 244, 524-535 (2006).
93. Ercolani, G. et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: Experience with 142 observed cases. Ann. Surg. Oncol. 12, 459-466 (2005). (Pubitemid 40884260)
94. Reddy, S. K. et al. Resection of noncolorectal nonneuroendocrine liver metastases: A comparative analysis. J. Am. Coll. Surg. 204, 372-382 (2007). (Pubitemid 46283502)
95. Weitz, J. et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann. Surg. 241, 269-276 (2005).
96. Yedibela, S. et al. Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: A single-institutional review. Ann. Surg. Oncol. 12, 778-785 (2005). (Pubitemid 41355929)
97. Fortner, J. G. & Fong, Y. Twenty-five-year follow-up for liver resection: The personal series of Dr. Joseph G. Fortner. Ann. Surg. 250, 908-913 (2009).
98. Touzios, J. G. et al. Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann. Surg. 241, 776-783 (2005).
99. Adam, R. et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann. Surg. 244, 897-907 (2006). (Pubitemid 44808622)
100. Hoffmann, K. et al. Liver resection for multimodal treatment of breast cancer metastases: Identification of prognostic factors. Ann. Surg. Oncol. 17, 1546-1554 (2010).
101. Thelen, A. et al. Liver resection for metastases from breast cancer. J. Surg. Oncol. 97, 25-29 (2008).
102. Vlastos, G. et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann. Surg. Oncol. 11, 869-874 (2004).
103. Rehders, A. et al. Hepatic metastasectomy for soft-tissue sarcomas: Is it justified? World J. Surg. 33, 111-117 (2009).
104. Okano, K. et al. Hepatic resection for metastatic tumors from gastric cancer. Ann. Surg. 235, 86-91 (2002). (Pubitemid 34062403)
105. Hsueh, E. C. et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 100, 122-129 (2004). (Pubitemid 37553547)
106. Mariani, P. et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur. J. Surg. Oncol. 35, 1192-1197 (2009).
107. Pawlik, T. M. et al. Hepatic resection for metastatic melanoma: Distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann. Surg. Oncol. 13, 712-720 (2006).
108. DeMatteo, R. P. et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg. 245, 347-352 (2007). (Pubitemid 46673128)
109. Ben-Josef, E. et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 23, 8739-8747 (2005). (Pubitemid 46211519)
110. Dawson, L. A. et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 18, 2210-2218 (2000). (Pubitemid 30350212)
111. Krishnan, S. et al. Conformal radiotherapy of the dominant liver metastasis: A viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am. J. Clin. Oncol. 29, 562-567 (2006). (Pubitemid 44915291)
112. Mohiuddin, M., Chen, E. & Ahmad, N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J. Clin. Oncol. 14, 722-728 (1996). (Pubitemid 26085515)
113. Kavanagh, B. D. et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 45, 848-855 (2006). (Pubitemid 44423131)
114. Schefter, T. E. et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int. J. Radiat. Oncol. Biol. Phys. 62, 1371-1378 (2005). (Pubitemid 40982057)
115. Blomgren, H., Lax, I., Näslund, I. & Svanström, R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 34, 861-870 (1995).
116. van der Pool, A. E. et al. Stereotactic body radiation therapy for colorectal liver metastases. Br. J. Surg. 97, 377-382 (2010).
117. Méndez Romero, A. et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol. 45, 831-837 (2006).
118. Hoyer, M. et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 45, 823-830 (2006). (Pubitemid 44423128)
119. Curley, S. A. et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann. Surg. 239, 450-458 (2004). (Pubitemid 38372760)
120. Gillams, A. R. The use of radiofrequency in cancer. Br. J. Cancer 92, 1825-1829 (2005). (Pubitemid 40826126)
121. Berber, E., Tsinberg, M., Tellioglu, G., Simpfendorfer, C. H. & Siperstein, A. E. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J. Gastrointest. Surg. 12, 1967-1972 (2008).
122. Abdalla, E. K. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg. 239, 818-825 (2004).
123. Bleicher, R. J. et al. Radiofrequency ablation in 447 complex unresectable liver tumors: Lessons learned. Ann. Surg. Oncol. 10, 52-58 (2003).
124. Elias, D. et al. Local recurrences after intraoperative radiofrequency ablation of liver metastases: A comparative study with anatomic and wedge resections. Ann. Surg. Oncol. 11, 500-505 (2004). (Pubitemid 40486731)
125. Lee, W. S. et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J. Clin. Gastroenterol. 42, 945-949 (2008).
126. Siperstein, A. E., Berber, E., Ballem, N. & Parikh, R. T. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann. Surg. 246, 559-565 (2007). (Pubitemid 47480598)
127. Solbiati, L. et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: Long-term results in 117 patients. Radiology 221, 159-166 (2001). (Pubitemid 32880383)
128. Gillams, A. R. & Lees, W. R. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur. Radiol. 14, 2261-2267 (2004). (Pubitemid 40057937)
129. Reuter, N. P., Woodall, C. E., Scoggins, C. R., McMasters, K. M. & Martin, R. C. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: Therapeutically equivalent? J. Gastrointest. Surg. 13, 486-491 (2009).
130. Gillams, A. R. & Lees, W. R. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur. Radiol. 19, 1206-1213 (2009).
131. Hildebrand, P. et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: Results in 88 patients. Langenbecks Arch. Surg. 391, 118-123 (2006).
132. Iannitti, D. A., Dupuy, D. E., Mayo-Smith, W. W. & Murphy, B. Hepatic radiofrequency ablation. Arch. Surg. 137, 422-426 (2002).
133. Machi, J. et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: Evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J. 12, 318-326 (2006). (Pubitemid 44285559)
134. Guckenberger, M. et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: Relevance of 4D dose calculation. Int. J. Radiat. Oncol. Biol. Phys. 74, 47-54 (2009).
135. Rosen, C. B. et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann. Surg. 216, 493-504 (1992).
136. Jamison, R. L. et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch. Surg. 132, 505-510 (1997).
137. Minagawa, M. et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results. Ann. Surg. 231, 487-499 (2000). (Pubitemid 30185854)
138. Wei, A. C. et al. Survival after hepatic resection for colorectal metastases: A 10-year experience. Ann. Surg. Oncol. 13, 668-676 (2006).
139. Shah, S. A. et al. Survival after liver resection for metastatic colorectal carcinoma in a large population. J. Am. Coll. Surg. 205, 676-683 (2007). (Pubitemid 47615495)
140. Ambrosino, G. et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: Preliminary results. Anticancer Res. 29, 3381-3384 (2009).